Description
El Grupo Español de Síndromes Mielodisplásicos (GESMD) tiene como fin principal fomentar y desarrollar la investigación sobre los Síndromes MIelodisplásicos (SMD), agrupando a todas aquellas personas dedicadas a la investigación, diagnóstico y tratamiento de los pacientes con estos procesos.
Su interés último es contribuir, junto a las personas afectadas por ellos y las instituciones, a alcanzar soluciones integrales que reduzcan o incluso erradiquen las consecuencias de este grupo de enfermedades. Los valores que sustentan estos objetivos son la independencia del colectivo profesional respecto de la industria farmacéutica y la búsqueda del beneficio social mediante el desarrollo y aplicación de terapias avanzadas contra los SMD.
Hide
Show More...
Su interés último es contribuir, junto a las personas afectadas por ellos y las instituciones, a alcanzar soluciones integrales que reduzcan o incluso erradiquen las consecuencias de este grupo de enfermedades. Los valores que sustentan estos objetivos son la independencia del colectivo profesional respecto de la industria farmacéutica y la búsqueda del beneficio social mediante el desarrollo y aplicación de terapias avanzadas contra los SMD.
Screenshots
GESMD Edición 2020 FAQ
-
Is GESMD Edición 2020 free?
Yes, GESMD Edición 2020 is completely free and it doesn't have any in-app purchases or subscriptions.
-
Is GESMD Edición 2020 legit?
Not enough reviews to make a reliable assessment. The app needs more user feedback.
Thanks for the vote -
How much does GESMD Edición 2020 cost?
GESMD Edición 2020 is free.
-
What is GESMD Edición 2020 revenue?
To get estimated revenue of GESMD Edición 2020 app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.
User Rating
App is not rated in Egypt yet.
Ratings History
GESMD Edición 2020 Reviews
Store Rankings
Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet
GESMD Edición 2020 Competitors
| Name | Downloads (30d) | Monthly Revenue | Reviews | Ratings | Recent release | |
|---|---|---|---|---|---|---|
Trasplante Hematopoyético 2022
|
Unlock
|
Unlock
|
0
|
|
2 years ago | |
Guía ECF
Enf. de células falciformes
|
Unlock
|
Unlock
|
0
|
|
2 years ago | |
NMV／r
Nirmatrelvir/r interactions
|
Unlock
|
Unlock
|
0
|
|
1 year ago | |
Systemic Mastocytosis
Identification and diagnosis
|
Unlock
|
Unlock
|
0
|
|
6 months ago | |
Keypoints in Hemostasia
|
Unlock
|
Unlock
|
0
|
|
6 months ago | |
Manual de Hematología 2022
|
Unlock
|
Unlock
|
0
|
|
2 years ago | |
Trialing
|
Unlock
|
Unlock
|
0
|
|
1 week ago | |
Protocol Expert Commitee
|
Unlock
|
Unlock
|
0
|
|
2 years ago | |
Riete Registry
|
Unlock
|
Unlock
|
0
|
|
2 months ago | |
Guía de Linfoma de GELTAMO
|
Unlock
|
Unlock
|
0
|
|
1 month ago |
GESMD Edición 2020 Installs
Last 30 days
GESMD Edición 2020 Revenue
Last 30 daysGESMD Edición 2020 Revenue and Downloads
Gain valuable insights into GESMD Edición 2020 performance with our analytics.
Sign up now to access downloads, revenue, and more.
Sign up now to access downloads, revenue, and more.
App Info
- Category
- Medical
- Languages
- English
- Recent release
- 1.4.8 (2 years ago )
- Released on
- Mar 23, 2021 (3 years ago )
- Also available in
- Norway , India , Italy , Japan , South Korea , Kuwait , Kazakhstan , Lebanon , Mexico , Malaysia , Nigeria , Netherlands , Israel , Peru , Philippines , Portugal , Romania , Saudi Arabia , Sweden , Singapore , Thailand , Ukraine , United States , Vietnam , Denmark , Argentina , Austria , Australia , Belgium , Brazil , Canada , Switzerland , Chile , China , Colombia , Germany , United Arab Emirates , Dominican Republic , Algeria , Ecuador , Egypt , Spain , Finland , France , United Kingdom , Hungary , Indonesia , Ireland
- Last Updated
- 1 month ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.